Einfluss von fäkalem Calprotectin auf klinische Entscheidungen bei Patienten mit Morbus Crohn und Colitis ulcerosa

Impact of faecal calprotectin measurement on clinical decision-making in patients with Crohn’s disease and ulcerative colitis

von Anna Luisa Bathe
Dissertation
Datum der mündl. Prüfung:2021-02-23
Erschienen:2021-02-22
Betreuer:PD Dr. Ahmad Amanzada
Gutachter:PD Dr. Ahmad Amanzada
Gutachter:Prof. Dr. Reinhard Hilgers
Gutachter:Prof. Dr. Martin Oppermann
Zum Verlinken/Zitieren: http://dx.doi.org/10.53846/goediss-8437

 

 

Dateien

Name:Dissertation_Bathe_eDiss.pdf
Size:822.Kb
Format:PDF

Lizenzbestimmungen:

Zusammenfassung

Englisch

Faecal calprotectin (FC) seems to be the best available biomarker for the detection of intestinal inflammation in patients with inflammatory bowel disease (IBD). The aim of this study is to clarify whether the measurement of FC has changed the number of ultrasound and endoscopic procedures, drug modifications, as well as FC re-measurements in IBD patients. This retrospective study included 254 IBD patients. Clinical consequences such as carrying out abdominal ultrasound, endoscopy, drug modification or FC re-measurement at the next ambulatory presentation or during in-patient stay were collected. Statistical analysis was performed to determine the association between clinical decision-making and patient’s characteristics, especially FC value. In CD patients with high FC values significantly increased numbers of abdominal ultrasounds, endoscopies and FC re-measurements were noted. In UC patients with high FC values significantly increased numbers of abdominal ultrasounds, drug modifications and FC re-measurements were noted. Measurement of FC may alter physician’s clinical decision-making in IBD patients beside other clinical and diagnostic parameters. Further prospective and survey studies are warranted to evaluate the influence of FC measurement in the daily clinical decisionmaking.
Keywords: Faecal calprotectin
 
Statistik